200 related articles for article (PubMed ID: 10390205)
1. DNA cleavage activities of Staphylococcus aureus gyrase and topoisomerase IV stimulated by quinolones and 2-pyridones.
Saiki AY; Shen LL; Chen CM; Baranowski J; Lerner CG
Antimicrob Agents Chemother; 1999 Jul; 43(7):1574-7. PubMed ID: 10390205
[TBL] [Abstract][Full Text] [Related]
2. Activities of trovafloxacin compared with those of other fluoroquinolones against purified topoisomerases and gyrA and grlA mutants of Staphylococcus aureus.
Gootz TD; Zaniewski RP; Haskell SL; Kaczmarek FS; Maurice AE
Antimicrob Agents Chemother; 1999 Aug; 43(8):1845-55. PubMed ID: 10428901
[TBL] [Abstract][Full Text] [Related]
3. Differential behaviors of Staphylococcus aureus and Escherichia coli type II DNA topoisomerases.
Blanche F; Cameron B; Bernard FX; Maton L; Manse B; Ferrero L; Ratet N; Lecoq C; Goniot A; Bisch D; Crouzet J
Antimicrob Agents Chemother; 1996 Dec; 40(12):2714-20. PubMed ID: 9124828
[TBL] [Abstract][Full Text] [Related]
4. Action of quinolones against Staphylococcus aureus topoisomerase IV: basis for DNA cleavage enhancement.
Anderson VE; Zaniewski RP; Kaczmarek FS; Gootz TD; Osheroff N
Biochemistry; 2000 Mar; 39(10):2726-32. PubMed ID: 10704224
[TBL] [Abstract][Full Text] [Related]
5. Streptococcus pneumoniae DNA gyrase and topoisomerase IV: overexpression, purification, and differential inhibition by fluoroquinolones.
Pan XS; Fisher LM
Antimicrob Agents Chemother; 1999 May; 43(5):1129-36. PubMed ID: 10223925
[TBL] [Abstract][Full Text] [Related]
6. Role of the extended alpha4 domain of Staphylococcus aureus gyrase A protein in determining low sensitivity to quinolones.
Strahilevitz J; Robicsek A; Hooper DC
Antimicrob Agents Chemother; 2006 Feb; 50(2):600-6. PubMed ID: 16436716
[TBL] [Abstract][Full Text] [Related]
7. Quinolones inhibit DNA religation mediated by Staphylococcus aureus topoisomerase IV. Changes in drug mechanism across evolutionary boundaries.
Anderson VE; Zaniewski RP; Kaczmarek FS; Gootz TD; Osheroff N
J Biol Chem; 1999 Dec; 274(50):35927-32. PubMed ID: 10585479
[TBL] [Abstract][Full Text] [Related]
8. Inhibitory activities of quinolones against DNA gyrase and topoisomerase IV purified from Staphylococcus aureus.
Tanaka M; Onodera Y; Uchida Y; Sato K; Hayakawa I
Antimicrob Agents Chemother; 1997 Nov; 41(11):2362-6. PubMed ID: 9371334
[TBL] [Abstract][Full Text] [Related]
9. Fluoroquinolones inhibit preferentially Streptococcus pneumoniae DNA topoisomerase IV than DNA gyrase native proteins.
Fernandez-Moreira E; Balas D; Gonzalez I; de la Campa AG
Microb Drug Resist; 2000; 6(4):259-67. PubMed ID: 11272253
[TBL] [Abstract][Full Text] [Related]
10. Cloning and primary structure of Staphylococcus aureus DNA topoisomerase IV: a primary target of fluoroquinolones.
Ferrero L; Cameron B; Manse B; Lagneaux D; Crouzet J; Famechon A; Blanche F
Mol Microbiol; 1994 Aug; 13(4):641-53. PubMed ID: 7997176
[TBL] [Abstract][Full Text] [Related]
11. The effect of moxifloxacin on its target topoisomerases from Escherichia coli and Staphylococcus aureus.
Schedletzky H; Wiedemann B; Heisig P
J Antimicrob Chemother; 1999 May; 43 Suppl B():31-7. PubMed ID: 10382873
[TBL] [Abstract][Full Text] [Related]
12. Antibacterial activities and inhibitory effects of sitafloxacin (DU-6859a) and its optical isomers against type II topoisomerases.
Akasaka T; Kurosaka S; Uchida Y; Tanaka M; Sato K; Hayakawa I
Antimicrob Agents Chemother; 1998 May; 42(5):1284-7. PubMed ID: 9593169
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of DNA gyrase and DNA topoisomerase IV of Staphylococcus aureus and Escherichia coli by aminocoumarin antibiotics.
Alt S; Mitchenall LA; Maxwell A; Heide L
J Antimicrob Chemother; 2011 Sep; 66(9):2061-9. PubMed ID: 21693461
[TBL] [Abstract][Full Text] [Related]
14. Target preference of 15 quinolones against Staphylococcus aureus, based on antibacterial activities and target inhibition.
Takei M; Fukuda H; Kishii R; Hosaka M
Antimicrob Agents Chemother; 2001 Dec; 45(12):3544-7. PubMed ID: 11709337
[TBL] [Abstract][Full Text] [Related]
15. Quinolone resistance mutations in topoisomerase IV: relationship to the flqA locus and genetic evidence that topoisomerase IV is the primary target and DNA gyrase is the secondary target of fluoroquinolones in Staphylococcus aureus.
Ng EY; Trucksis M; Hooper DC
Antimicrob Agents Chemother; 1996 Aug; 40(8):1881-8. PubMed ID: 8843298
[TBL] [Abstract][Full Text] [Related]
16. Purification of pneumococcal type II topoisomerases and inhibition by gemifloxacin and other quinolones.
Morrissey I; George JT
J Antimicrob Chemother; 2000 Apr; 45 Suppl 1():101-6. PubMed ID: 10824040
[TBL] [Abstract][Full Text] [Related]
17. Dual targeting of topoisomerase IV and gyrase to reduce mutant selection: direct testing of the paradigm by using WCK-1734, a new fluoroquinolone, and ciprofloxacin.
Strahilevitz J; Hooper DC
Antimicrob Agents Chemother; 2005 May; 49(5):1949-56. PubMed ID: 15855518
[TBL] [Abstract][Full Text] [Related]
18. Selective targeting of topoisomerase IV and DNA gyrase in Staphylococcus aureus: different patterns of quinolone-induced inhibition of DNA synthesis.
Fournier B; Zhao X; Lu T; Drlica K; Hooper DC
Antimicrob Agents Chemother; 2000 Aug; 44(8):2160-5. PubMed ID: 10898691
[TBL] [Abstract][Full Text] [Related]
19. Mutations in topoisomerase IV and DNA gyrase of Staphylococcus aureus: novel pleiotropic effects on quinolone and coumarin activity.
Fournier B; Hooper DC
Antimicrob Agents Chemother; 1998 Jan; 42(1):121-8. PubMed ID: 9449271
[TBL] [Abstract][Full Text] [Related]
20. DNA gyrase of Staphylococcus aureus and inhibitory effect of quinolones on its activity.
Takahata M; Nishino T
Antimicrob Agents Chemother; 1988 Aug; 32(8):1192-5. PubMed ID: 2847648
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
